Figure 1. Model Framework.

The 2-part model included a short-term decision tree and a long-term Markov model. CAR-T indicates chimeric antigen receptor T-cell therapies; SCT, stem cell transplantation.

^aPatients who discontinue owing to manufacturing failure will transition to the active comparator. Patients who discontinue owing to adverse event will receive no further antileukemic or antilymphomic therapy and will enter the semi-Markov partitioned survival model at M2.

^bPatients who transition from M1 to M2 will receive palliative therapy.